Novavax Inc (WBO:NVAX)
€ 9.276 -0.09 (-0.96%) Market Cap: 1.49 Bil Enterprise Value: 734.28 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 47/100

Novavax, Inc. - Special Call Transcript

Mar 24, 2020 / 12:30PM GMT
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Novavax NanoFlu achieves all primary endpoints in the Phase III clinical trials conference call. (Operator Instructions)

I would now like to introduce your host for today's conference call, Ms. Erika Trahan, Senior Manager of Investor Relations and Public Relations. You may begin.

Erika S. Trahan
Novavax, Inc. - Senior Manager of Investor & Public Relations

Thank you, operator. Good morning. I'd like to thank everyone who has joined today's call to discuss our Phase III NanoFlu results. A press release announcing our results is currently available on our website at novavax.com, and an audio archive of this conference call will be available on our website later today.

Joining me on today's call are Stan Erck, President and CEO of Novavax; John Trizzino, Chief Business Officer and Chief Financial Officer; and Dr. Gregory Glenn, our President of Research and Development, will be available for the Q&A portion of the call.

Before we begin with prepared remarks,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot